mechlorethamine has been researched along with Epstein-Barr Virus Infections in 3 studies
nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.
Epstein-Barr Virus Infections: Infection with human herpesvirus 4 (HERPESVIRUS 4, HUMAN); which may facilitate the development of various lymphoproliferative disorders. These include BURKITT LYMPHOMA (African type), INFECTIOUS MONONUCLEOSIS, and oral hairy leukoplakia (LEUKOPLAKIA, HAIRY).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Griffin, BE | 1 |
| Kanakry, JA | 1 |
| Li, H | 1 |
| Gellert, LL | 1 |
| Lemas, MV | 1 |
| Hsieh, WS | 1 |
| Hong, F | 1 |
| Tan, KL | 1 |
| Gascoyne, RD | 1 |
| Gordon, LI | 1 |
| Fisher, RI | 1 |
| Bartlett, NL | 1 |
| Stiff, P | 1 |
| Cheson, BD | 1 |
| Advani, R | 1 |
| Miller, TP | 1 |
| Kahl, BS | 1 |
| Horning, SJ | 1 |
| Ambinder, RF | 1 |
| Tirelli, U | 1 |
| Vaccher, E | 1 |
| Spina, M | 1 |
| Carbone, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease[NCT00003389] | Phase 3 | 854 participants (Actual) | Interventional | 1999-06-17 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Overall survival is defined as the time from randomization to death or last known alive. The 5-year survival rate is the probability a patient survives 5 years. (NCT00003389)
Timeframe: Assessed every 2 months if patient is < 1 year from study entry, every 3 months for the second year, every 4 months for the third year, every 6 months for years 4 and 5, and yearly for 5 years
| Intervention | Proportion of patients (Number) |
|---|---|
| Arm A (ABVD) | 0.88 |
| Arm B (Stanford V) | 0.88 |
"Failure-free survival is defined as the time from randomization to the earlier of progression/relapse or death. The 5-year failure-free survival is the probability a patient is failure-free and survives 5 years.~Progression is defined as an increase in size of 25% of the sum of the products of the pretreatment measurements or appearance of new lesions. Significant enlargement of the liver or spleen is evidence of progression. A significant increase in size is defined as > 2.0 cm in distance between costal margin and the inferior margin of either organ.~Relapse is defined as the re-appearance of any clinical evidence of Hodgkin's disease in a patient who has had a complete response. Relapse for partial responders is defined as progressive disease relative to disease status during the partial remission." (NCT00003389)
Timeframe: Assessed every 2 months if patient is < 1 year from study entry, every 3 months for the second year, every 4 months for the third year, every 6 months for years 4 and 5
| Intervention | Proportion of patients (Number) |
|---|---|
| Arm A (ABVD) | 0.74 |
| Arm B (Stanford V) | 0.71 |
Number of patients who developed second primary cancers (NCT00003389)
Timeframe: Assessed every 2 months if patient is < 1 year from study entry, every 3 months for the second year, every 4 months for the third year, every 6 months for years 4 and 5, and yearly for 5 years
| Intervention | participants (Number) |
|---|---|
| Arm A (ABVD) | 15 |
| Arm B (Stanford V) | 19 |
1 review available for mechlorethamine and Epstein-Barr Virus Infections
| Article | Year |
|---|---|
Hodgkin's disease: clinical presentation and treatment.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Combined | 2001 |
1 trial available for mechlorethamine and Epstein-Barr Virus Infections
| Article | Year |
|---|---|
Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 2013 |
1 other study available for mechlorethamine and Epstein-Barr Virus Infections
| Article | Year |
|---|---|
[Nasopharyngeal carcinoma in sub-Saharan Africa: a tribute to Mr. Peter Clifford].
Topics: Africa South of the Sahara; Antineoplastic Agents, Alkylating; Burkitt Lymphoma; Epstein-Barr Virus | 2009 |